Bupropion

Research Update

Varenicline and Bupropion: Soaring Again With EAGLES?

Topics: Addiction | Addiction Treatment | Bupropion | Chantix | Co-occurring disorders | Dual diagnosis | FDA Warnings | Medication | Pharmacology | Research | Research Update | Side Effects | Smoking Cessation | Smoking Cessation Agents | Substance Use | Substance use disorders | Suicidality | Suicide | Tobacco | Varenicline | Wellbutrin

Review of: Anthenelli RM et al, Lancet 2016;387(10037):2507–2520 Varenicline (Chantix) and bupropion (Zyban and others) are effective treatments for tobacco use disorder, but their use (and sales) took a big hit in 2009 when the FDA slapped both with black box warnings linking them to psychiatric complications, including suicidal ideation. Although

Read More
Clinical Update

Treating Sexual Dysfunction in Women

Topics: Addyi | Alternative treatments | Bupropion | Complimentary treatments | Female hypoactive sexual desire disorder | Female Issues in Psychiatry | natural treatments | Sex Therapy | Vyleesi

With the marketing of two new treatments for female sexual dysfunction, one thing is certain: You can expect to see more patients asking for these medications. What’s less certain is whether they will work. Flibanserin (Addyi) and bremelanotide (Vyleesi), the two FDA-approved treatments, both have small effect sizes (0.3–0.4) on various measures o

Read More
Research Update

Does Augmenting Varenicline with Bupropion Work Better than Varenicline Alone?

Topics: Bupropion | Research Update | Smoking Cessation | Varenicline

Review Of: Cinciripini PM et al, Addiction 2018;113:1673-1682 We have a good array of smoking cessation treatments to choose from, including nicotine replacement therapy (NRT), bupropion, and varenicline. Varenicline is the most effective monotherapy agent, somewhat better than bupropion and single-product NRT, and comparable to combination NRT. Theo

Read More